Home > Boards > US Listed > Biotechs > Neon Therapeutics (NTGN)

The findings in the Immunity publication demonstrate that

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
m1999 Member Profile
Member Level 
Followed By 863
Posts 71,049
Boards Moderated 35
Alias Born 03/10/09
160x600 placeholder
Termination of Registration of a Class of Security Under Section 12(b) (15-12b) Edgar (US Regulatory) - 5/18/2020 6:09:23 AM
Post-effective Amendment to an S-8 Filing (s-8 Pos) Edgar (US Regulatory) - 5/6/2020 5:10:57 PM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 5/6/2020 5:04:38 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/6/2020 4:47:18 PM
Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ... Edgar (US Regulatory) - 5/6/2020 10:48:39 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/5/2020 5:11:22 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/1/2020 8:39:04 AM
Neon Therapeutics Announces Acceptance of European Clinical Trial Authorization Application for NEO-PTC-01 GlobeNewswire Inc. - 4/30/2020 7:00:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/29/2020 5:33:24 PM
Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) Edgar (US Regulatory) - 4/29/2020 5:31:48 PM
Amended Annual Report (10-k/a) Edgar (US Regulatory) - 4/21/2020 4:31:49 PM
WeissLaw LLP Investigates Neon Therapeutics, Inc. PR Newswire (US) - 4/10/2020 7:45:00 PM
Proxy Statement - Merger or Acquistion (definitive) (defm14a) Edgar (US Regulatory) - 4/2/2020 5:00:12 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 4/2/2020 9:01:53 AM
Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) Edgar (US Regulatory) - 3/31/2020 5:10:59 PM
Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) Edgar (US Regulatory) - 3/31/2020 4:06:38 PM
Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) Edgar (US Regulatory) - 3/31/2020 7:56:45 AM
BioNTech Announces Full Year 2019 Financial Results and Corporate Update GlobeNewswire Inc. - 3/31/2020 6:42:46 AM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 3/27/2020 2:29:41 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/25/2020 5:29:39 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 3/23/2020 8:17:14 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/2/2020 6:40:21 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/2/2020 6:40:09 PM
m1999 Member Level  Thursday, 09/05/19 10:55:44 PM
Re: None
Post # of 14 
The findings in the Immunity publication demonstrate that Neon’s proprietary class II prediction algorithms substantially outperform NetMHCIIpan, the current benchmark for class II prediction. Key findings in the research include the development of novel proteomic strategies that resolve over 40 MHC class II motifs and the observation that intra-tumoral MHC class II presentation is dominated by professional antigen presenting cells (APCs) rather than tumor cells. Tracking which tumor epitopes are most readily phagocytosed and presented by APCs further enhances the ability to pinpoint therapeutically relevant epitopes.

A proprietary approach powering Neon’s RECON bioinformatics platform for MHC class I molecules was first described in an earlier article published in Immunity in 2017.


STOP & VISIT MY BOARD AT: HOTTEST PENNY STOCK PICKS

http://investorshub.advfn.com/boards/board.aspx?board_id=19627

My posts are NOT a buy/sell recommendation, Do your Own DD, before you buy any stock - I reserve the right to buy/sell any stock
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences